Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Right Ventricular Function After Successful Reopening of Right Coronary Versus Left Circumflex Chronic Total Occlusions

15 novembre 2026 mis à jour par: Amr Abdelbadee Abdelhameed Othman, Assiut University

Changes in Right Ventricular Function Following Successful Right Coronary Versus Left Circumflex Chronic Total Occlusion Revascularization

This study will compare changes in the function of the right side of the heart after successful treatment of a long-standing complete blockage in either the right coronary artery or the left circumflex coronary artery. Patients will receive catheter-based treatment because their clinical team has independently decided that it is appropriate; the study will not assign their artery or treatment technique.

The planned comparison includes 160 patients with successful treatment, with 80 in each artery group. Heart ultrasound will be performed within 14 days before the procedure and again six months afterward. A telephone follow-up will take place at three months. Conventional ultrasound measurements and speckle tracking, which measures deformation of the heart muscle, will be used to assess right ventricular function. The main comparison is the change in right ventricular free-wall longitudinal strain between the two groups.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

Design and setting:

Prospective, single-centre observational cohort at Assiut University Heart Hospital, with consecutive recruitment within two prespecified vessel strata. Elective percutaneous coronary intervention (PCI) is selected independently of research participation. The operator determines the clinical PCI technique. No research treatment assignment, stress test, additional catheterization, experimental drug, biomarker assay or SAQ-7 questionnaire is required.

Cohort formation:

Baseline written consent and research echocardiography precede PCI. The main comparison comprises technically successful index procedures: residual stenosis less than 30% with final TIMI 3 flow. One index attempt per patient defines cohort entry. Unsuccessful procedures are recorded descriptively in the screening log and do not contribute to the primary successful-procedure comparison. Procedural complications do not retrospectively redefine technical success. The planned main cohort is 80 RCA and 80 LCX patients; this is distinct from the number of patients screened or consented before PCI.

Recruitment schedule:

Anticipated recruitment is from 1 January 2027 through 30 June 2028. Each participant is followed for six months after index PCI, with the specified visit window. Recruitment end is distinct from final outcome collection.

Assessments:

Baseline clinical and resting echo assessment occurs within 14 days before PCI; repeat baseline if an intervening acute event occurs. Angiographic anatomy, procedure strategy, result, complications and discharge treatment are recorded at the index admission. Three-month telephone contact, with a 14-day window, records vital status, symptoms, admissions and medication changes and reminds participants of the six-month visit. Six-month resting echo and clinical reassessment allow a 30-day window. Late assessments are retained for sensitivity analysis.

Imaging:

Conventional two-dimensional echocardiography and RV speckle tracking are performed using a Philips system with AutoStrain RV, after verification of installed software, native RVFWSL/RV4CSL outputs and image export. Manufacturer, model and software version are documented. An RV-focused apical four-chamber view is acquired, with at least three stable ECG-linked cycles. Patient-level outputs are averaged across three acceptable cycles. Native global free-wall strain is the primary measure; four-chamber strain includes the septum. Signed source values are preserved. Images with persistent tracking failure are not replaced by another endpoint. Conventional measurements include FAC, TAPSE, tissue-Doppler S-prime and RV basal diameter. LVEF, LV volumes, valve regurgitation, E/e-prime and estimated pulmonary artery systolic pressure provide clinical context. PASP is recorded only when technically measurable.

Anatomical characterization:

Coronary dominance, CTO location relative to major branches, previous target-territory infarction, collateral supply, residual coronary disease and J-CTO score are recorded. All dominance patterns are eligible. The LCX cohort is a disease comparator, not a healthy control.

Sample-size rationale:

The target of 160 successful cases uses assumed planning inputs: a 2-percentage-point between-group difference in individual strain magnitude change, a common change SD of 4 points, two-sided alpha 0.05 and 80% power. A noncentral-t calculation requires 64 complete patients per group, increased to 80 per group for 20% incomplete paired assessment. These assumptions are not direct RCA-versus-LCX effect estimates or established minimal clinically important differences. At an assumed 85% success rate, approximately 95 eligible attempts per vessel stratum may be needed; this is a planning estimate rather than observed local recruitment data.

Analysis:

The primary endpoint is compared using a two-sided Welch t test with a 95% confidence interval. Supportive ANCOVA models six-month strain magnitude with vessel group, baseline strain magnitude, baseline LVEF, age, prior myocardial infarction and coronary dominance. The primary complete-pair estimand concerns survivors with successful index PCI and interpretable baseline and follow-up imaging. Deaths, failed procedures, withdrawals and tracking failures are reported separately; post-death strain is not imputed. Missing survivor outcomes are addressed by multiple imputation when feasible and sensitivity analyses. Signed-strain analysis, patient-level bootstrap intervals and analysis excluding major interval events are prespecified sensitivity checks. Formal secondary testing of RV4CSL, FAC, TAPSE and S-prime uses Holm correction. Segmental strain and symptom analyses are exploratory. Clinical events are descriptive; the study is not powered for mortality or major cardiovascular events and does not establish a causal effect of PCI.

Quality and ethics:

A separate technical run-in of 10-15 cases checks acquisition and analysis feasibility. Twenty-five paired examinations are randomly selected for interobserver and intraobserver repeat analysis; readers are blinded to group and visit order where feasible. Written consent and required institutional and ethics approvals precede research procedures. Coded records and image files are stored securely with the identity key separately. Clinical care remains independent of participation.

Type d'étude

Observationnel

Inscription (Estimé)

160

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Clinically stable adults attending Assiut University Heart Hospital with one native RCA or LCX chronic total occlusion and an independently established clinical indication for elective PCI. Consecutive eligible patients are assessed within each vessel stratum. The main comparison targets 80 technically successful index procedures in each group. Consent and baseline research imaging precede PCI; unsuccessful index procedures are recorded descriptively outside the main comparative cohort.

La description

Inclusion Criteria:

  • Age 18 years or older.
  • Clinically stable, with one native right coronary or left circumflex coronary artery chronic total occlusion, defined by TIMI 0 flow and documented or estimated duration of at least three months.
  • Independently selected for clinically indicated elective PCI.
  • Sinus rhythm and interpretable baseline RV-focused echocardiographic images.
  • Written informed consent before research procedures.
  • For inclusion in the main comparison: technically successful index CTO PCI, defined as residual stenosis less than 30% with final TIMI 3 flow.

Exclusion Criteria:

  • Acute coronary syndrome or myocardial infarction within 30 days.
  • Decompensated heart failure.
  • A second untreated chronic total occlusion.
  • Previous coronary artery bypass graft surgery.
  • Significant congenital heart disease.
  • Moderate or severe valvular heart disease.
  • Severe nonischemic pulmonary disease or pulmonary hypertension dominating RV dysfunction.
  • Persistent atrial fibrillation or paced rhythm preventing comparable analysis.
  • Inadequate baseline RV tracking.
  • Planned non-target revascularization during follow-up; clinically required other-vessel treatment should be completed before baseline when stable.

No arbitrary LVEF threshold is imposed. All coronary dominance patterns are eligible. Interval clinical deterioration, target-vessel failure, medication changes or clinically required subsequent revascularization do not retrospectively exclude an enrolled patient; they are recorded and follow-up is retained whenever possible.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Successful RCA CTO PCI

Adults with one native right coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol.

Elective PCI of a right coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure.

Resting ultrasound assessment within 14 days before index PCI and at six months, with a 30-day follow-up window. Includes RV free-wall and four-chamber strain and conventional RV measures. No stress test is required.

Successful LCX CTO PCI

Adults with one native left circumflex coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol.

Resting ultrasound assessment within 14 days before index PCI and at six months, with a 30-day follow-up window. Includes RV free-wall and four-chamber strain and conventional RV measures. No stress test is required.

Elective PCI of a left circumflex coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in right ventricular free-wall longitudinal strain magnitude
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Individual change is the absolute magnitude of six-month RV free-wall longitudinal strain minus its baseline absolute magnitude, measured in percentage points. Native Philips RVFWSL output is used and signed source values are retained. A positive magnitude change denotes greater systolic shortening. The primary comparison is the difference in mean individual change between the RCA and LCX cohorts. For illustration only, a change from -20% to -23% equals +3 percentage points in magnitude; this is not an observed result or the assumed between-group effect.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in right ventricular four-chamber longitudinal strain magnitude
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Change in native RV4CSL magnitude, including free wall and septum, from baseline to six months, in percentage points. Positive change denotes greater shortening magnitude; signed source values are preserved.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in right ventricular fractional area change
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline RV fractional area change (FAC), in percentage points. FAC is 100 times (end-diastolic area minus end-systolic area) divided by end-diastolic area in an RV-focused view.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in tricuspid annular plane systolic excursion
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline TAPSE, in millimetres, measured by aligned M-mode at the lateral tricuspid annulus.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in tricuspid annular systolic tissue-Doppler velocity
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline systolic S-prime velocity, in centimetres per second, measured by pulsed tissue Doppler at the lateral tricuspid annulus.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in right ventricular basal diameter
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline RV basal diameter, in millimetres, measured in the RV-focused apical four-chamber view.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in Canadian Cardiovascular Society angina class
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Baseline and six-month CCS angina class and individual class transitions are recorded. Classes I through IV indicate progressively greater limitation by angina; a lower class denotes improvement. This is an exploratory clinical secondary outcome.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in New York Heart Association functional class
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Baseline and six-month NYHA functional class and individual class transitions are recorded. Classes I through IV indicate progressively greater functional limitation; a lower class denotes improvement. This is an exploratory clinical secondary outcome.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Change in basal right ventricular free-wall segmental longitudinal strain magnitude
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Exploratory six-month minus baseline magnitude change in basal RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in mid right ventricular free-wall segmental longitudinal strain magnitude
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Exploratory six-month minus baseline magnitude change in mid RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in apical right ventricular free-wall segmental longitudinal strain magnitude
Délai: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Exploratory six-month minus baseline magnitude change in apical RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chaise d'étude: Hatem A. Helmy, MD, Department of Cardiovascular Medicine, Faculty of Medicine, Assiut University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 janvier 2027

Achèvement primaire (Estimé)

31 janvier 2029

Achèvement de l'étude (Estimé)

31 janvier 2029

Dates d'inscription aux études

Première soumission

15 novembre 2026

Première soumission répondant aux critères de contrôle qualité

15 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • AssiutU-CARD-AAAO-0002

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

The IPD might not be shared according to the local institutional policy.

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .